CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS

摘要

The invention concerns novel cyclin-dependent kinase (CDK) and glycolene synthase kinase-3 (GSK-3) inhibitors, corresponding to general formula (I), wherein: A represents a hydrogen atom, a halogen atom, a formyl, cyano, nitro, guanidinoaminomethylenyl, (1,3-dihydro-2-oxoindol)-3-ylidenemethyl, alkylcarbonyl, aralkylcarbonyl or heteroaralkylcarbonyl radical, or a -L-NR<1>R<2> radical wherein L represents an alkylene radical and R<1> and R<2> are selected independently among a hydrogen atom and an alkyl radical or R<1> and R<2> together with the nitrogen bearing them form a heterocycle with 5 to 7 members optionally substituted; X represents a hydrogen atom, an alkylthio, aralkylthio, alkylthioxo or aralkylthioxo radical, or a NR<4>R<5> radical wherein R<4> represents an alkyl radical, a hydroxyalkyl radical, a cycloalkyl radical optionally substituted, an aralkyl radical whereof the aryl radical is optionally substituted, or R<4> represents a heteroaryl or heteroarylalkyl radical, the heteroaryl radical of the heteroaryl or heteroarylalkyl radicals being optionally substituted; Y represents NH or an oxygen atom; Z represents a bond or an alkyl or alkylthioalkyl radical; and Ar represents a carbocyclic aryl radical optionally substituted, a heterocyclic aryl radical optionally substituted or a piridiniumolate radical; or are pharmaceutically acceptable salts of said compounds.